PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16877311

Improved efficiency of budesonide nebulization using surface-active agents.

A M Bouwman·M P Heijstra·N C Schaefer·E J Duiverman·P N Lesouëf·S G Devadason
View original source ↗Export metadata ↓

Abstract

Our aim was to improve the efficiency of nebulised budesonide using surface-active agents. Cationic, anionic, and nonionic detergents were added to commercial budesonide suspension, and the particle size distribution during nebulization was measured using both cascade impaction and laser diffraction. Our results showed that the emitted dose was increased after addition of cationic (p < 0.001) and nonionic detergents (p < 0.01) compared with the commercial formulation alone. The respirable fraction was increased for all detergent formulations (p < 0.001) compared with the commercial formulation. We concluded that cationic and nonionic detergent increased the total output of budesonide from the Sidestream. All detergent formulations increased the respirable fraction of nebulized budesonide.

Explore related subjects

Administration, InhalationBronchodilator AgentsBudesonideDetergentsDrug Delivery SystemsIn Vitro TechniquesLasersNebulizers and VaporizersParticle SizeRefractometrySolubilitySurface-Active AgentsTechnology, PharmaceuticalComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A M Bouwman, M P Heijstra, N C Schaefer, E J Duiverman, P N Lesouëf, S G Devadason. Improved efficiency of budesonide nebulization using surface-active agents.. https://doi.org/10.1080/10717540500458862

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗